Recent evidence further suggest that feedback activation of STAT3-signaling plays prominent role in mediating drug resistance to a broad spectrum of anti-cancer therapies, and IL6/STAT3 pathway inhibitors can serve as effective means to eradicate CSCs [57,59]. The gene discussed is STAT3; the disease is cancer.